Evidence map›Paper›PMID 37504312›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Artificial Intelligence Applied to a First Screening of Naevoid Melanoma: A New Use of Fast Random Forest Algorithm in Dermatopathology.

Gerardo Cazzato, Alessandro Massaro, Anna Colagrande, Irma Trilli, Giuseppe Ingravallo, Nadia Casatta, Carmelo Lupo, Andrea Ronchi, Renato Franco, Eugenio Maiorano and 1 more

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Gerardo CazzatoSection of Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0003-0325-4316
Alessandro MassaroLUM Enterprise srl, S.S. 100-Km.18, Parco il Baricentro, 70010 Bari, Italy.ORCID 0000-0003-1744-783X
Anna ColagrandeSection of Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0003-4676-0761
Irma TrilliOdontomatostologic Clinic, Department of Innovative Technologies in Medicine and Dentistry, University of Chieti "G. D'Annunzio", 66100 Chieti, Italy.ORCID 0000-0002-2882-025X
Giuseppe IngravalloSection of Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-4792-3545
Nadia CasattaInnovation Department, Diapath S.p.A., Via Savoldini n.71, 24057 Martinengo, Italy.ORCID 0000-0002-4861-0727
Carmelo LupoInnovation Department, Diapath S.p.A., Via Savoldini n.71, 24057 Martinengo, Italy.ORCID 0000-0003-3287-7299
Andrea RonchiPathology Unit, Department of Mental Health and Physic and Preventive Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Renato FrancoPathology Unit, Department of Mental Health and Physic and Preventive Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Eugenio MaioranoSection of Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-0472-5338
Angelo VaccaCentro Interdisciplinare Ricerca Telemedicina-CITEL, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-4567-8216
University of Bari Aldo Moro · ITUniversity of Campania "Luigi Vanvitelli" · ITLUM Jean Monnet University · ITUniversity of Chieti-Pescara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant melanoma (MM) is the "great mime" of dermatopathology, and it can present such rare variants that even the most experienced pathologist might miss or misdiagnose them. Naevoid melanoma (NM), which accounts for about 1% of all MM cases, is a constant challenge, and when it is not diagnosed in a timely manner, it can even lead to death. In recent years, artificial intelligence has revolutionised much of what has been achieved in the biomedical field, and what once seemed distant is now almost incorporated into the diagnostic therapeutic flow chart. In this paper, we present the results of a machine learning approach that applies a fast random forest (FRF) algorithm to a cohort of naevoid melanomas in an attempt to understand if and how this approach could be incorporated into the business process modelling and notation (BPMN) approach. The FRF algorithm provides an innovative approach to formulating a clinical protocol oriented toward reducing the risk of NM misdiagnosis. The work provides the methodology to integrate FRF into a mapped clinical process.

Indexed as

Artificial IntelligenceMelanomaAlgorithmsCutaneous Malignant MelanomaHumansRandom Forestalgorithmartificial intelligence (AI)BPMN clinical processesdermatopathologyfast random forest (FRF)naevoid melanoma (NM)

Identifiers

PMID37504312
PMCPMC10378276
OpenAlexW4382023412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.